Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients

<div>Comorbidity prevalence per group. The prevalence of relevant comorbidities like hypertension, diabetes, COPD, cardiovascular disease, and chronic bronchitis was calculated for each treatment group. L/R: lopinavir/ritonavir; Chlo: chloroquine; L/R+Chlo: lopinavir/ritonavir plus chloroquine; ST: standard treatment; COPD: chronic obstructive pulmonary disease.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients 

Figure 3 | Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients 